SRPK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL407224	0.45	10/20
SCHEMBL721543	0.45	9/20
SCHEMBL897572	0.72	8/20
SCHEMBL898519	0.50	8/20
SCHEMBL897486	0.72	7/20
SCHEMBL897390	0.70	7/20
SCHEMBL897598	0.66	7/20
SCHEMBL898305	0.63	7/20
SCHEMBL897866	0.49	7/20
SCHEMBL1755787	0.48	7/20
SCHEMBL898411	0.44	7/20
SCHEMBL898431	0.45	6/20
SCHEMBL1755949	0.59	5/20
SCHEMBL897125	0.57	5/20
SCHEMBL7428870	0.37	5/20
SCHEMBL898387	0.64	4/20
SCHEMBL896828	0.57	4/20
SCHEMBL897943	0.57	4/20
SCHEMBL408023	0.42	4/20
SCHEMBL898134	0.40	4/20

Clinical trials — most relevant to SRPK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
SRSF2 Gene Mutation in Patients With t-MDS/AML	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs	nan	UNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Genetic Investigation of Cancer Predisposition	nan	NOT_YET_RECRUITING
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SRPK2 binder may also engage these)

Protein	Name	Similarity
O54781	—	1.000	O54781 →
O70551	—	0.991	O70551 →
Q5RD27	—	0.990	Q5RD27 →
Q03656	—	0.990	Q03656 →
SRPK1	SRSF protein kinase 1	0.989	landscape →
P36616	—	0.989	P36616 →
A0A1D9QMS2	—	0.987	A0A1D9QMS2 →
Q61IS6	—	0.987	Q61IS6 →
Q03563	—	0.986	Q03563 →
Q9Z0G2	—	0.986	Q9Z0G2 →
A2QHV0	—	0.986	A2QHV0 →
Q92539	—	0.986	Q92539 →
O14328	—	0.986	O14328 →
Q8WML3	—	0.985	Q8WML3 →
A8X0C4	—	0.985	A8X0C4 →
Q2QMH1	—	0.985	Q2QMH1 →
Q5XIK8	—	0.985	Q5XIK8 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.985	landscape →
A6ZZF6	—	0.985	A6ZZF6 →
Q9GN62	—	0.985	Q9GN62 →
Q641K5	—	0.985	Q641K5 →
Q6L5F7	—	0.985	Q6L5F7 →
DYRK3	Dual specificity tyrosine-phosphorylation-regulated kinase 3	0.985	landscape →
Q63553	—	0.984	Q63553 →
Q4R8E0	—	0.984	Q4R8E0 →
Q0WPH8	—	0.984	Q0WPH8 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.984	landscape →
Q08BS4	—	0.984	Q08BS4 →
Q9LV37	—	0.984	Q9LV37 →
Q8RX66	—	0.984	Q8RX66 →